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periodic attacks of wheezing, shortness of breath, 
tightness in the chest, and coughing, particularly at 
night or in the early morning.[1,2] According to the 
studies, 5% of the world’s population that is about 300 
millions of people worldwide, are currently infected 
with the disease whose prevalence increases by 50% 
for every 10 years.[3] Worldwide, approximately 180,000 
deaths annually are related to asthma although the 
mortality rate has generally declined since the year 
1980.[3,4]
INTRODUCTION
Now-a-day, chronic lung diseases are among the most 
prevalent diseases causing disability and mortality, 
among which asthma, as one of the most common 
diseases, has signifi cant prevalence and incidence. 
Asthma is a chronic infl ammatory disease of the airways 
that leads to airway narrowing through the processes 
of infl ammation and smooth muscle contraction in 
airway walls (bronchoconstriction). Symptoms include 
Background: Formoterol and salmeterol are two long-acting β2-agonists given by inhalation, with bronchodilating eff ects lasting 
for at least 12 h after a single administration. Formoterol has a faster onset of action compared with salmeterol. Th e aim of this 
study was to perform a systematic review and meta-analysis on the data published from previous review in order to calculate pooled 
estimates of eff ectiveness and safety assessment of formoterol and salmeterol in treatment of patients with asthma. Materials and 
Methods: In this study, we conducted an electronic search for medical citation databases including Cochrane, PubMed, Scopus, 
PsycInfo, and IranMedex. Besides manual search of the databases that record randomized clinical trials, conference proceedings, 
and journals related to asthma were included. Studies were evaluated by two independent people based on inclusion and exclusion 
criteria, and the common outcomes of studies were entered into the RevMan 5.0.1 software, after evaluation of studies and extraction 
of data from them; and in cases where there were homogeneous studies, meta-analysis was performed, and for heterogeneous studies, 
the results were reported qualitatively. Results: Of the 1539 studies initially found, 13 were included in the study. According to the 
meta-analysis conducted, no signifi cant diff erence was found between the inhalation of formoterol 12 μg and salmeterol 50 μg in the 
two outcomes of mean forced expiratory volume 1 s (FEV1), 12 h after inhalation of medication and Borg score (A frequently used 
scale for quantifying breathlessness) after inhalation of medication. In addition, salmeterol was more eff ective than formoterol in 
the two outcomes of percent decrease in FEV1 after inhalation of methacholine and the number of days without an attack. Since the 
two outcomes of FEV1 30-60 min after inhalation of medication and morning peak expiratory fl ow after inhalation of medication 
were heterogeneous, they had no meta-analysis capabilities, and its results were reported qualitatively. Conclusion: Th e data from 
included studies shows that, more effi  cacy has been achieved with Salmeterol, especially in some outcomes such as the percent 
decrease in FEV1 after inhalation of Methacholine, and the number of days without an attack; and therefore, the administration of 
Salmeterol seems to be benefi cial for patients, compared with Formoterol.
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Study of the prevalence of asthma symptoms, according to 
a meta-analysis on the country-level which was performed 
by Heidarnia et al. between 1378 and 1383, showed that 
the prevalence of the symptoms is diff erent in children 
in diff erent regions of the country and varies between 
2.7% in Kerman and 35.4% in Tehran. According to this 
study, the mean prevalence of asthma symptoms across 
the country were obtained in 13.14% (95% confidence 
interval [CI]: 9.97-16.30%).[5] Formoterol and salmeterol 
are two long-acting β2-agonist given by inhalation, with 
bronchodilating effects lasting for at least 12 h after a 
single administration.[6,7] Both of these drugs have become 
valuable complements in the regular treatment of asthmatic 
patients who are not satisfactorily controlled with inhaled 
corticosteroids.[8] Formoterol has a faster onset of action 
within 5 min compared with salmeterol that has a slower 
onset of action within 15-20 min.[9]
In today’s world where there are limited resources to meet 
unlimited health care needs of the people, the importance 
of informed decision-making with the least chance of 
error in the health sector and the lack of resources in our 
country is essential, because the use of a new drug in the 
treatment can be accompanied by various complications and 
diff erent tolerance levels, and signifi cant price diff erence 
can be found between the use of existing drugs and a 
new drug. This study is conducted to evaluate the safety 
and eff ectiveness of formoterol versus salmeterol in the 
treatment of patients with asthma.
MATERIALS AND METHODS
We conducted a systematic review and meta-analysis. 
Diff erent phases of the study included searching, screening, 
and selecting of studies, extracting data and data cleaning 
and analyzing.
Search strategy
To retrieve related studies, we used a sensitive search 
strategy in medical citation databases including, Cochran 
Library, PubMed, Scopus, PsycInfo, and IranMedex. In 
addition, we performed manual search of the databases that 
record randomized clinical trials, conference proceedings, 
and journals related to asthma such as American Academy 
of Allergy, Asthma and Immunology, American Thoracic 
Society, Asia Pacific Society of Respirology, British 
Thoracic Society Winter Meeting, and other journal such 
as Allergology International, Clinical Drug Investigation, 
American Journal of Respiratory and Critical Care Medicine, 
Journal of Asthma, and Canadian Respiratory Journal. Also, 
we checked health.govandopen.gov in case of complication 
of medications. In order to fi nd the dissertation proposal, 
Dissertation Abstracts Online was searched, and then an 
alert was generated in Google Scholar during the execution 
of new articles to be achieved.
In search protocol, we were used in the combination of the 
MeSH terms “formoterol,” “salmeterol” and “asthma.”
The last search in databases was performed on July 10, 2012. 
Search was updated on February 24, 2013 but new records 
were not found.
The following search strategy was conducted for library 
Cochrane and then adapted to the other resources.
#1Formoterol#Atock#3Oxeze#4Oxis#5Foradil#6Foradile
#7Perforomist#8EFormoterol#9eFormoterol#10Aerolizer#
11BD 40A#12AstraZeneca#13Formoterol fumarate#143-
formylamino-4-hydroxy-alpha#15arFormoterol#16Schering 
(brand of Formoterol fumarate)#17Atimos #18(#1 OR #4 OR #5 
OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR 
#15 OR #17)#19Salmeterol#20Serevent#21GlaxoWellcome(bra
ndof Salmeterolxinafoate)#22Salmeterol xinafoate #23(#19 OR 
#20 OR #21 OR #22)#24(#18 AND #23)#25Asthma#26MeSH 
descriptor Asthma explode all trees#27(#25 OR #26) #28(#24 
AND #27).
We did not limit our search to a certain language or time 
period to avoid missing possibly related works. Besides, we 
factored in manual reference checking and citation tracking 
of related paper. All the studies inserted in the EndNoteX4 
Thomson Reuters’s soĞ ware and duplicates were excluded, 
and then the titles and abstracts were reviewed based on 
inclusion and exclusion criteria.
Inclusion criteria
Clinical trials that have designed as crossover or parallel 
studies or have conducted as double-blind or open, or have 
compared adult asthmatic patients treated with formoterol 
and salmeterol, were entered into the study.
Exclusion criteria
The following were excluded from the study: Trials that 
have been performed in vitro and trials that have examined 
the patients suffering from diseases with differential 
diagnosis of asthma (such as chronic obstructive 
pulmonary disease, exercise-induced asthma, nocturnal 
asthma, and asthma in children), the use of formoterol in 
combination with other drugs such as budesonide, and 
the use of salmeterol in combination with other drugs 
such as fl uticasone.
 Study selection
Full-text of the relevant studies was critically appraised 
for eligibility criteria by two researchers independently. 
The third colleague assessed the papers in case of 
disagreement. Formoterol unrelated and duplicated 
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articles were excluded based on title and abstract. Flow 
diagram of studies included in the systematic review is 
shown in Figure 1.
Quality assessment
Studies that met the inclusion criteria of our review were 
independently evaluated by two researchers in a qualitative 
manner, according to Cochran indices. Also we used the 
Jadad quality assessment scale (JADAD scale) in order for 
quality assessment.
Although the quality was not used as a case for excluding 
studies, it was considered in the fi nal conclusion when 
evaluating the results of studies.
Data synthesis
Data extraction forms were designed for the data extracted 
from papers, which were checked by the second person. 
Common outcomes of papers were entered into the RevMan 
5.0.1 Cochrane Collaboration’s soĞ ware: The outcomes of 
this study were entered into the “Data Analysis” section 
of the soĞ ware in a continuous quantitative manner; the 
sub-outcomes entered the data of related studies; and the 
mean diff erence and CI (95%) were calculated based on a 
fi xed-eff ect model. Homogeneity and heterogeneity were 
evaluated using I2 and Chi-square tests based on the P 
value. For the outcomes of homogeneous studies, the meta-
analysis data were used in this study while the data were 
qualitatively reported for the outcomes of heterogeneous 
studies.
RESULTS
One thousand three hundred and thirty-six of 1536 articles 
found in this study remained aĞ er removing duplicate 
cases: Thirty-three studies met the study’s inclusion criteria 
on the basis of title and abstract; and concerning eight 
articles whose original printed versions were not found, 
the decision was made based on the titles and abstracts 
available, according to inclusion and exclusion criteria of 
the study. Thirteen of 25 studies were excluded, the reason 
for exclusion are described in Table 1. At last, 12 studies 
whose data are listed in Table 2 met the inclusion criteria 
of the review. Flow diagram of selecting studies is shown 
in Figure 1.
The total number of participants in the 12 studies was 
1661. The outcomes selected in these studies were forced 
expiratory volume 1 s (FEV1) and Borg score in two studies, 
FEV1 in six studies, peak expiratory fl ow (PEF) in one study, 
episode-free days (EFDs) and quality of life in one study, 
and PEF and EFDs in one study, as well as FEV1 and PEF 
Figure 1: Flowchart of the selection process records
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in one study. The doses of salmeterol were equal to 50 μg 
twice daily in nine studies, 100 μg twice daily in one study, 
both doses in one study, and uncertain dose in one study. 
The doses of formoterol were equal to 12 μg twice daily in 
eight studies, 24 μg twice daily in one study, 12 and 24 μg 
in one study, doses of 6, 12, and 24 μg in one study, and 
uncertain dose in one study.
The results of evaluating the homogeneity and heterogeneity 
of studies, which was done based on I2 and Chi-square tests 
according to the P value, are as follows.
Meta-analysis of the outcomes with mean forced 
expiratory volume 1 s, 12 h aĞ er inhalation of the drug
Three studies of Palmqvist et al.,[23] Grembiale et al.,[24] 
Table 1: Reason for exclusion of 13 studies
First author Year Reason for exclusion
Singhania et al.[10] 2008 The study was conducted in a population of children that were not consistent in our study
Lee et al.[11] 2004 Combination of medication was used in the intervention and comparison
Richter et al.[12] 2002 Asthma due to exercise has been considered
van der Woude et al.[13] 2001 Combination of medication was used in the intervention and comparison
Lipworth et al.[14] 2000 The study was performed on patients with a specifi c genotype
Aziz et al.[15] 1998 Formoterol and salmeterol were not used in this study
Tan et al.[16] 1997 Formoterol and salmeterol were not used in this study
Brambilla et al.[17] 2003 Combination of medication was used in the intervention and comparison
van Veen et al.[18] 2003 The effect of these drugs was compared with short-acting drugs
Schermer et al.[19] 2004 The study was conducted in patients with persistent asthma
Politiek et al.[20] 1999 Combination of medication was used in the intervention and comparison
Eryonucu et al.[21] 2005 Effects on heart rate changes were measured
Cates and Lasserson[22] 2010 Combination of medication was used in the intervention and comparison
Table 2: Details of included studies specifi cation
First author Year Country Study setting 
and time period
Sample Dosage of 
salmeterol
Dosage of 
formoterol
Outcome Quality 
score
Rutten-van 1998 UK, Switzerland 
Sweden, France, 
Spain, Italy
RCT
6 months
482 50 μg
Twice a day
12 μg
Twice a day
EFDs
Quality of life
2
John J. Condemi 2001 USA RCT
6 months
528 50 μg
Twice a day
12 μg
Twice a day
EFDs
PEF
2
Julia A. Nightingale 2002 UK RCT
4 months
528 50 μg
Twice a day
12 μg
Twice a day
PEF
FEV1
4
Klaus F. Rabe 1993 Germany RCT
1-day
12 50 μg
100 μg
Once a day
12 μg
24 μg
Once a day
FEV1 2
Campbell 1999 UK RCT
8 weeks
469 50 μg
Twice a day
12 μg
Twice a day
PEF 2
Palmqvist 1997 Sweden RCT
12 h
28 50 μg
NA
6 μg
12 μg
24 μg
NA
FEV1 4
H. J van der Woude 2001 Netherland RCT
2 weeks
19 100 μg
Twice a day
24 μg
Twice a day
FEV1
Borg score
5
Hanneke J. van der Woude 2004 Netherland RCT
4 days
21 50 μg
Twice a day
12 μg
Twice a day
FEV1
Borg score
4
Rosa D. Grembiale 2002 Italy RCT
3 days
10 50 μg
Twice a day
12 μg
Twice a day
FEV1 2
Alison Grove 1996 UK RCT
12 h
10 50 μg
NA
12 μg
NA
FEV1 1
Brian J. Lipworth 1998 Scotland RCT
10 days
10 50 μg
Twice a day
12 μg
Twice a day
FEV1 1
Valentine Lemaigre 2006 Belgium RCT
NA
30 NA NA FEV1 2
NA =Not available; RCT = Randomized clinical trials; FEV1 = Forced expiratory volume in 1 s; PEF = Peak expiratory fl ow; EFDs = Episode-free days
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and Rabe et al.[25] were included following outcomes. 
These studies were homogeneous, and meta-analysis was 
performed (χ2 = 0.14, P = 0.93, I2 = 0%). Forest plot of these 
studies is shown in Figure 2.
According to the meta-analysis results, mean diff erence 
was −0.02 (−0.22, 0.18); there is no difference between 
formoterol 12 μg and salmeterol 50 μg in mean FEV1 at 12 
h aĞ er inhalation of medication. According to the JADAD 
score of studies with this outcome, this lack of diff erence 
appears to be valid in the mean FEV1. 
Meta-analysis of the outcomes with reduced forced 
expiratory volume 1 s aĞ er inhalation of methacholine
Two studies from van der Woude et al.[26,27] were included in 
this analysis. These studies were homogeneous, and meta-
analysis was performed (χ2 = 0.44, P = 0.51, I2 = 0%). Forest 
plot of these studies is shown in Figure 3.
According to the meta-analysis results, this is a signifi cant 
difference as 5.23 (1.11-9.34). Therefore, the use of 
salmeterol 50 μg aĞ er inhalation of methacholine reduced 
more the FEV1 than that of formoterol 12 μg; in these two 
studies, the ratio dosage of formoterol to salmeterol is 
same and these studies are similar in this regard, so this 
point has been considered as restitution of this analysis, 
and these results should be taken with caution. Also, 
van der Woude study was sponsored by AstraZeneca 
Company but in another study did not mention the 
confl ict of interest.
Meta-analysis of outcomes with the number of days 
without an aĴ ack
Two studies of RuĴ en-van Mölken et al.[28] and Condemi[29] were 
included in this analysis. These studies were homogeneous, 
and meta-analysis was performed (χ² = 0.00, P = 0.96, I2 = 0%). 
Forest plot of these studies is shown in Figure 4.
According to the meta-analysis results, mean difference was 
1.71 (0.19, 3.22); this difference is statistically signifi cant, and 
therefore, the number of days without an attack after use of 
salmeterol 50 μg is more than that of formoterol 12 μg. However, 
the difference was not clinically comparable, and their results 
should be taken with caution because a review of the quality 
evaluation of these two articles indicates a medium quality. These 
studies were sponsored by Novartis Company.
Meta-analysis of the outcome with Borg score after 
inhalation of drugs
Two studies from van der Woude were included in this 
analysis.[26,27] These studies were homogeneous, and meta-
analysis was performed (χ² =0.05, P = 0.82, I2 = 0%). Forest 
plot of these studies is shown in Figure 5.
According to the meta-analysis results, this difference is not 
statistically signifi cant as 0.06 (−1.95, 2.06) and, therefore, 
there is no difference in the score after inhalation of 50 μg 
salmeterol and 12 μg formoterol, in these two studies, the ratio 
dosage of formoterol to salmeterol is same and two studies 
are similar in this regard, so this point has been considered 
as restitution of this analysis, and these results should be 
taken with caution. Also, van der Woude was sponsored by 
Figure 2: Forest plot of the outcome with mean forced expiratory volume 1 s, 12 h after inhalation of the drug
Figure 3: Forest plot of the outcomes with reduced forced expiratory volume 1 s after inhalation of methacholine
Velayati, et al.: Effectiveness and safety of formoterol vs salmeterol
Journal of Research in Medical Sciences| May 2015 | 488
AstraZeneca company but in another study did not mention 
the confl ict of interest.
DISCUSSION
According to the study result, there was no difference found 
between salmeterol (12 μg) and formoterol (50 μg) in two 
meta-analyses, and in two other meta-analyses, the results were 
also in favor of salmeterol (50 μg). Due to their heterogeneous 
nature, the two outcomes of FEV1 30-60 min after inhalation 
of medication and morning PEF after inhalation of medication 
had no meta-analysis capabilities, whose results were reported 
qualitatively. In both meta-analyses, there were two studies 
where, for each outcome, they were in favor of the intervention 
group (formoterol 12 μg) in one study and in favor of the control 
group (salmeterol 50 μg) in another study. There is also evidence 
about the safety and effectiveness of formoterol and salmeterol 
that are as follows.
The complaints observed in the two drug groups of 
salmeterol and formoterol were similar in the studies by 
Campbell and RuĴ en-van the laĴ er of which was funded 
by the Novartis Corporation.[28] Condemi’s study, which 
was funded by the Novartis Corporation, showed that 
the complications of upper respiratory tract infection, 
aggravation of asthma, headache, and rhinitis in the 
formoterol group were more than those in the salmeterol 
group, while the complications of viral infections, sinusitis, 
bronchitis, cough, pharyngitis, and pain in the salmeterol 
group were more than those in the formoterol group. In 
Nightingale’s study, complaints observed in the formoterol 
group were more than those in the salmeterol group.[30]
The most common side complaints reported in the study 
of Condemi were upper respiratory tract infection, 
asthma, viral infection, sinusitis, bronchitis, headache, 
rhinitis, and cough; no deaths were reported in any of 
the groups.[29]
In Campbell’s study, in total, 1171 side eff ects were reported 
during the study (during implementation and duration 
of treatment) by 390 cases, several of whom had reported 
more than one adverse complication. In this study, the 
complications observed in both drug groups were almost 
identical and statistically insignifi cant. In Nightingale’s 
study, the complications observed are (17 of 35 patients, 
49%) in the formoterol group, and (13 of 33 patients, 
39%) in the salmeterol group, type of complications is not 
mentioned in this study; during the study, one patient in the 
formoterol group had suff ered a transient ischemic aĴ ack. 
In the study by RuĴ en-van et al., 11 of 241 patients in the 
formoterol group and 12 of 241 patients in the salmeterol 
group have had complications. However, they were not 
noted in the study. Also, the side eff ects of these drugs were 
not mentioned in other studies.
Only 2 of the 4 studies where side effects of the drugs have been 
documented have reported details of the observed complications, 
and the others had just mentioned the number of complications 
observed. Brands of formoterol used in the four studies include 
Novartis in two studies, Oxis in one study, and Foradil in one 
study; and brands of salmeterol used are GlaxoSmithKline in 
two studies, Serevent and Glaxo-Wellcome in one study, and 
Serevent in one study. Formoterol 12 μg and salmeterol 50 
μg were prescribed twice daily in all 4 studies. Whereas the 
duration of use was not mentioned in two studies, in two other 
Figure 4: Forest plot of outcomes with the number of days without an attack
Figure 5: Forest plot of the outcome with Borg score after inhalation of drugs
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studies, the drug was administrated for 24 weeks (108 days) 
and 166 (±36) days.
Taking salmeterol 50 μg after inhalation of methacholine 
can reduce more the FEV1 than formoterol 12 μg (P = 0.01, 
CI = [1.11, 9.34]). The number of days without an attack after 
taking salmeterol 50 μg is the more than that after taking 
formoterol 12 μg (P = 0.03, CI = [0.19, 3.22]). In mean FEV1 
at 12 h after inhalation of medication, there is no difference 
between formoterol 12 μg and salmeterol 50 μg (P = 0.82, 
CI = [−0.22, 0.18]). Also, there is no difference in the score 
after inhalation of 50 μg salmeterol and 12 μg formoterol (P = 
0.956, CI = [−1.95, 2.06]).
In the studies included in the review, there were no 
signifi cant diff erences between the two drugs, in terms of 
effi  ciency and effi  cacy. Furthermore, in the study by RuĴ en-
van et al., there was no signifi cant diff erence between the 
two drugs in terms of outcomes and/or costs, and physicians 
in each country were advised to use the drug with a lower 
price, which seems to be in line with the results of this 
project.[10] Overall, the safety and eff ectiveness of formoterol 
seem to be not more than those of salmeterol; and compared 
to formoterol, the administration of salmeterol appears 
to be benefi cial for patients, because salmeterol is being 
domestically produced in Iran and is readily available in 
pharmacies in the country.
Limitation of this study
The weaknesses of this study include lack of access to some 
databases such as EMBASE, due to the database being 
closed in Iran and not fi nding the full-text of eight studies 
that had been conducted on this subject, but there were no 
published articles about them.
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